Posted: October 4, 2007
The FDA is seeking public comments on expanding "Behind-the-Counter" (BTC) status to cover more drugs.
In a notice set to be published in today's Federal Register, the agency announced a Nov. 14 hearing to explore "the public health benefit of drugs being available without a prescription but only after intervention by a pharmacist." (WSJ: See "FDA May Ease Prescription-Drug Rules").
In the Federal Register notice, FDA suggests many questions it would like comment on, which don't include any about regulating the advertising for BTC drugs.
For more on this, read today's post to Pharma Marketing Blog.
For more posts in related topic areas, see:
If you wish to receive notice by email whenever a post is made to Pharma Marketing Blog, please subscribe.
| Return to Pharma Marketing Blog Topics |